TScan Therapeutics, Inc. (TCRX) – What Are Researchers Thinking About This Stock?

TScan Therapeutics, Inc. (NASDAQ:TCRX) has earned a consensus rating of “Hold” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $2.67.

A number of equities analysts have commented on TCRX shares. Wedbush downgraded shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a report on Wednesday, September 2nd. Benchmark reiterated a “buy” rating on shares of TScan Therapeutics in a research note on Thursday, August 13th. HC Wainwright cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price for the company. in a research report on Tuesday, September 8th. Lifesci Capital downgraded shares of TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. Finally, Weiss Ratings lowered shares of TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 8th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC boosted its stake in shares of TScan Therapeutics by 19.6% in the first quarter. Renaissance Technologies LLC now owns 1,364,783 shares of the company’s stock worth $1,378,000 after buying an additional 223,714 shares during the last quarter. BlackRock Inc. acquired a new stake in TScan Therapeutics during the second quarter worth about $975,000. GSA Capital Partners LLP purchased a new position in TScan Therapeutics during the second quarter valued at approximately $537,000. NewEdge Wealth LLC purchased a new position in TScan Therapeutics during the second quarter valued at approximately $90,000. Finally, Kestra Advisory Services LLC acquired a new position in TScan Therapeutics in the first quarter valued at approximately $63,000. 82.83% of the stock is owned by institutional investors and hedge funds.

TScan Therapeutics Trading Down 10.5%

Shares of TCRX opened at $0.17 on Tuesday. The company’s fifty day simple moving average is $0.36 and its 200-day simple moving average is $0.85. The company has a market cap of $11.83 million, a P/E ratio of -0.19 and a beta of 1.15. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 0.31. TScan Therapeutics has a twelve month low of $0.17 and a twelve month high of $1.97.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. The firm had revenue of $1.05 million during the quarter, compared to analyst estimates of $1.88 million. TScan Therapeutics had a negative net margin of 1,655.35% and a negative return on equity of 108.72%. As a group, analysts expect that TScan Therapeutics will post -0.79 EPS for the current year.

About TScan Therapeutics

TScan Therapeutics, Inc is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer. Its approach involves genetically modifying a patient’s T cells to recognize specific cancer-related antigens, with the goal of directing the immune system to attack malignant cells.

The company’s pipeline includes investigational therapies for hematologic malignancies and solid tumors. Its lead programs, TSC-100 and TSC-101, are designed to target the HA-1 antigen in patients with certain blood cancers following an allogeneic hematopoietic stem cell transplant.